Jinhai Medical Technology Limited (Stock Code: 2225) disclosed that on 25 February 2026, its indirect wholly owned subsidiary, Jinhai Technology Development (Shanghai) Co., Ltd. (“Jinhai SH”), and Shanghai Emphasis Investment Management Consulting Co., Ltd. (“Shanghai Emphasis Investment”) entered into a capital contribution agreement with Jinhai Biomedical Technology (Shanghai) Co., Ltd. (“Jinhai Biomedical”).

Under the agreement, Jinhai Biomedical’s paid-up registered capital will increase from RMB5.00 million to RMB25.00 million. The additional RMB20.00 million will be contributed in proportion to Jinhai Biomedical’s existing shareholding ratio: Jinhai SH will contribute RMB10.20 million (51%), and Shanghai Emphasis Investment will contribute RMB9.80 million (49%).

Jinhai Biomedical, established in January 2026, focuses on the wholesale and distribution of medical devices. Its principal shareholders, Jinhai SH and Shanghai Emphasis Investment, will retain their 51% and 49% equity interests, respectively, following the capital injection. The agreement aims to strengthen the subsidiary’s balance sheet and support its business development.

As Shanghai Emphasis Investment is controlled by certain associates of an executive director of Jinhai Medical (2225), the regulators consider Jinhai Biomedical a connected subsidiary under the Listing Rules. The transaction remains subject to reporting and announcement requirements, though it is exempt from circular and independent shareholders’ approval due to the size tests being below the prescribed thresholds.

Jinhai Medical (2225) is incorporated in the Cayman Islands. Its operating subsidiaries provide minimally invasive surgery solutions, medical products, manpower outsourcing, dormitory services, IT services, and construction ancillary services.